<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drugDebug/PMC7054296/results/search/test_trace/results.xml">
  <result pre="7054296290 doi: 10.1038/s41422-020-0290-0 : Editorial Virus against virus: a potential" exact="treatment" post="for 2019-nCov (SARS-CoV-2) and other RNA viruses NguyenTuan M.1ZhangYang1PandolfiPier"/>
  <result pre="1,384 deaths. This raises an urgent need for an effective" exact="treatment" post="of the deadly disease. However, current antiviral drugs have"/>
  <result pre="countries and a flexible CRISPR/Cas13d strategy for treating 2019-nCov(SARS-CoV-2) virus" exact="infection" post="and countering its evolution. a, b Sequence analysis of"/>
  <result pre="AAV design carrying Cas13d effector and a three-gRNA array for" exact="treatment" post="of patients with 2019-nCov (SARS-CoV-2) infection. ITR inverted terminal"/>
  <result pre="has also been tested in phase I trials for the" exact="treatment" post="of HIV and SARS-CoV.4 CRISPR/Cas13d is an RNA-guided, RNA-targeting"/>
  <result pre="Cas13d can be driven by tissue-specific promoters to achieve precise" exact="treatment" post="of infected organs. Additionally, AAV has serotypes highly specific"/>
  <result pre="potentially a straightforward, flexible, and rapid novel approach for the" exact="treatment" post="and prevention of RNA virus infection. Future studies determining"/>
 </snippets>
</snippetsTree>
